Clinical trials: Genetic Hemochromatosis
Iron Overload
Iron Overload in Stem Cell Transplant Recipients
The goal of this study is to examine the impact of iron overload in patients undergoing a bone marrow transplant. We believe that the iron status in these patients is associated with complications for transplant survivors.
- Trial name
- NCT00806715
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Boston Children's Hospital
Myocardial Iron Overload, HFE-Associated Hereditary Hemochromatosis
Estimation of Myocardial Iron Overload by 3 Tesla MRI in HFE Hereditary Haemochromatosis
Hereditary haemochromatosis (HHC) is a frequent disease in Brittany (5 to 7‰), responsible first for biological disorder in blood iron parameters and minor clinical disorders, before evolving to potential life-threatening…
- Trial name
- HEMOCOEUR (NCT02099214)
- Testing
- 3Tesla cardiac MRI, Electrocardiogram (EKG), Iron and cardiac markers
- Where
- France
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Rennes University Hospital
Hemochromatosis
Treatment of Hemochromatosis
This study will evaluate the effectiveness of a test called MCV in guiding phlebotomy (blood drawing) therapy in patients with hemochromatosis an inherited disorder that causes too much iron to be absorbed by the intestine.
- Trial name
- NCT00007150
- Testing
- Phlebotomy
- Where
- United States
- Volunteers
- 622 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Iron Overload, Thalassemia Major
"Iron Overload and Endocrinological Diseases"
Patients with hemochromatosis or Thalassemia develop progressive tissue and organs damages secondary to iron overload. Iron overload can result both from transfusional hemosiderosis and excess gastrointestinal iron absorption.
- Conditions
- Iron Overload, Thalassemia Major, Thalassemia Intermedia, Hemochromatosis
- Trial name
- NCT06137079
- Where
- Italy
- Volunteers
- 62 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Hemochromatosis Type 1
Impact of Bloodletting on Iron Metabolism in Type 1 Hemochromatosis
Hemochromatosis type 1 is one of the most frequent genetic disease since the genetic predisposition (homozygosity for the C282Y mutation of the HFE gene) is encountered in about 3/1000 white subjects (5/1000 in Brittany, France).
- Trial name
- SAIFER (NCT01810965)
- Testing
- First evaluation phase : no intervention / Second evaluation phase: bloodletting of 7 ml/kg (with a maximum of 500ml)
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Rennes University Hospital
Glomerulonephritis, Membranous, Neonatal Diseases and Abnormalities
Research Network for Neonatal Diseases Induced by Tissular Fetomaternal Alloimmunization
Problems of compatibility between a mother and her child are frequent. The most well-known case can be illustrated by the fetomaternal blood group incompatibility (rhesus factor) which can induce severe anemia of the fetus.
- Conditions
- Glomerulonephritis, Membranous, Neonatal Diseases and Abnormalities, Hemochromatosis
- Trial name
- NCT00199628
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Limoges
Hereditary Hemochromatosis
A Study to Evaluate BBI-001 in Healthy Volunteers and in Patients With Hereditary Hemochromatosis
This study will be conducted in two parts run in parallel. Part 1 of the study (Phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose) will enroll healthy volunteers in 3 sequential dose escalating…
- Trial name
- NCT07371793
- Testing
- BBI-001
- Where
- Australia
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Bond Biosciences
Anemia, Sickle Cell
Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions
The purpose of this study is to determine if the new orally active iron chelator, ICL670, is as safe as deferoxamine in preventing accumulation of iron in the body while a patient is undergoing repeated blood transfusions.
- Trial name
- NCT00067080
- Testing
- ICL670, deferoxamine
- Where
- 34 sites in United States
- Volunteers
- 195 people
- Sponsor
- Novartis Pharmaceuticals
Beta-Thalassemia, Thalassemia Major
Efficacy Study of the Use of Sequential DFP-DFO Versus DFP
Changes in chelation treatment and transfusion practices, during the past two decades, have dramatically improved the prognosis of thalassemia major patients.Deferiprone (DFP) has been compared with deferoxamine (DFO), using…
- Trial name
- SEQDFPDFO (NCT00733811)
- Testing
- Deferiprone (DFP) and Deferoxamine (DFO), Deferiprone (DFP)
- Where
- Italy
- Volunteers
- 213 people
- Sponsor
- Azienda Ospedaliera V. Cervello
Dysmetabolic Iron Overload Syndrome, Genetic Hemochromatosis
Effects of Polyphenols on Iron Absorption in Iron Overload Disorders.
Dysmetabolic iron overload syndrome and genetic hemochromatosis are frequent causes of iron overload. Polyphenols are efficient iron-chelators.
- Conditions
- Dysmetabolic Iron Overload Syndrome, Genetic Hemochromatosis, Iron Absorption, Polyphenols
- Trial name
- POLYFER (NCT03453918)
- Testing
- polyphenols
- Where
- France
- Volunteers
- 41 people
- Sponsor
- University Hospital, Clermont-Ferrand